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Abstract
Background: Short-chain fatty acids (SCFAs) may play a role in the pathophysiology of 
irritable bowel syndrome (IBS). This study analyzed fecal SCFAs after performing fecal 
microbiota transplantation (FMT) in the IBS patients who were included in our previ-
ous study of the efficacy of FMT.
Methods: This	study	included	142	of	the	164	IBS	patients	who	participated	in	our	pre-
vious study. They were belonging to three groups: placebo (own feces), 30-g (superdo-
nor	feces),	and	60-g	(superdonor	feces)	FMT.	The	patients	completed	the	IBS	Severity	
Scoring System (IBS-SSS) Birmingham IBS Symptom, Fatigue Assessment Scale (FAS), 
the IBS Quality of Life (IBS-QoL) and Short-Form Nepean Dyspepsia Index (SF-NDI) 
questionnaires and delivered fecal samples at the baseline and 1 month after FMT. The 
SCFA levels were determined by vacuum distillation followed by gas chromatography.
Key Results: The fecal butyric acid level was significantly increased after FMT in both 
the	30-g	and	60-g	groups	(both	P	≤	0.001).	In	the	60-g	group,	the	levels	of	total	SCFAs	
and isobutyric, isovaleric, and valeric acids increased after FMT. Butyric acid levels 
in	the	responders	in	both	the	30-g	and	60-g	FMT	groups	were	significantly	inversely	
correlated with IBS-SSS and FAS scores (P = 0.001, r	=	−0.3	and	P = 0.0001. r =- 0.3, 
respectively). There were no differences in the SCFA levels in the placebo group after 
FMT.
Conclusion and Inferences: FMT increases the fecal SCFA levels in IBS patients. The 
increase in the butyric acid level is inversely correlated with symptoms in IBS patients 
following FMT, suggesting that SCFAs might play a role in the pathophysiology of IBS. 
www.clini caltr ials.gov (NCT03822299).
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1  |  INTRODUC TION
The intestinal bacterial profile in patients with irritable bowel syn-
drome (IBS) differs from that in healthy subjects.2 The intestine of 
IBS patients has a lower abundance of butyrate-producing bacteria 
(Erysipelotrichaceae and Ruminococcaceae spp.) and a higher abun-
dance of methane-producing bacteria (Methanobacteriales spp.) 
compared with healthy subjects.2 In addition, the intestine of IBS pa-
tients has a higher abundance of Lactobacillus and Ruminococcus spp. 
and a lower abundance of Bifidobacterium, Faecalibacterium, 
and Erysipelotrichaceae spp. compared with healthy subjects.2 
Moreover, the diversity of intestinal bacteria (dysbiosis) is lower in 
patients with IBS than in healthy subjects.2 In experimental animals, 
alterations in the intestinal bacteria are associated with gut dys-
motility, visceral hypersensitivity, and altered intestinal permeabil-
ity.2 All of these abnormalities are observed in patients with IBS.2 
Thus, the gut microbiota is believed to play an important role in the 
pathophysiology of IBS.2 The gut microbiota is influenced by dietary 
modifications and nutritional supplements, which might explain the 
beneficial effects of different dietary regimes on IBS symptoms.3
Short-chain fatty acids (SCFAs) are the main products of bacterial 
fermentation of undigested and unabsorbed carbohydrates in the 
intestine.3 SCFAs are the main energy source for colonic epithelial 
cells, regulating gut barrier functions and local immune defenses.3 
Among the SCFAs, butyric acid has anti-inflammatory and intesti-
nal regenerative effects and administration of sodium butyrate to 
patients with inflammatory bowel disease changes the gut bacterial 
composition and induce the growth of butyric acid-producing bac-
terial genera.3
The fecal SCFA levels differ between IBS patients and healthy 
subjects, with the fecal propionic acid level being significantly higher 
in IBS patients.3 Whereas the levels of propionic and butyric acids 
were lower in constipation-predominant IBS (IBS-C) patients than 
in healthy subjects, that of butyric acid in diarrhea-predominant IBS 
(IBS-D) patients was higher.3
A recent randomized double-blind placebo-controlled study per-
formed by our group found that using a single superdonor for fecal 
microbiota transplantation (FMT) reduced IBS symptoms and fatigue 
and improved the quality of life in patients with IBS.4 These improve-
ments were accompanied by marked changes in the bacterial pro-
files of the patients.4 The present study investigated whether FMT 
caused alterations in the fecal SCFAs in the same cohort of patients 
that we investigated in our previous study.
2  |  MATERIAL S AND METHODS
2.1  |  Study design and randomization of patients
The design of this study has been described in detail previously.4 
In brief, patients provided a fecal sample and completed five ques-
tionnaires to assess their symptoms and quality of life at the base-
line and provided another fecal sample and completed a new set of 
questionnaires at 1 month after FMT. Polyethylene glycol and lop-
eramide were allowed as rescue medication during the study. The 




our previous study.4 They were belonging to three groups: placebo 
(48	 patients),	 30-g	 (50	 patients),	 and	60-g	 (44	 patients)	 FMT.	 The	
characteristics of these patients are given in Table 1. The patients 
enrolled in this study have been described in detail previously.4 In 
brief, patients who fulfilled the Rome IV criteria for a diagnosis of IBS 
were recruited from those attending the outpatient clinic at Stord 
Hospital. None of the patients had previously consumed a low-
FODMAPs (fermentable oligo-, di-, monosaccharides, and polyols) 
diet, and all of the recruited patients had previously adhered to the 
National Institute for Health and Care Excellence (NICE)-modified 
diet for at least 3 months without experiencing any marked im-
provement in symptoms; the patients were therefore considered 
as non-responders to this diet.4 They also received a course of IBS 
treatment that slightly improved their symptoms.4 Dysbiosis in the 
fecal samples was done by the GA-map Dysbiosis Test® (Genetic 
Analysis)	using	16S	 rRNA	gene.5 The patients were not tested for 
small intestinal bacterial overgrowth or bile acid malabsorption.
The inclusion criteria were being aged 18-85 years and having 
moderate-to-severe	IBS	symptoms,	as	indicated	by	a	score	of	≥175	
on the IBS Severity Scoring System (IBS-SSS). The exclusion criteria 
were the presence of systemic disease, immune deficiency or being 
treated by immune-modulating medication, pregnant, planning preg-
nancy, lactating, having a severe psychiatric disorder, having alcohol 
or drug abuse, or taking probiotics, antibiotics, or IBS medications 
within 8 weeks prior to study inclusion.
Key Points
• Fecal short-chain fatty acid (SCFA) levels differ between 
patients with irritable bowel syndrome (IBS) and healthy 
subjects. Abnormalities in SCFAs in patients with IBS 
might contribute to the pathophysiology of IBS.
• SCFAs increased after fecal microbiota transplantation 
(FMT) in patients with IBS. The compositions of fecal 
SCFAs at the baseline and after FMT differed with the 
IBS subtype. The changes in SCFAs varied with the ap-
plied FMT dose. The butyric acid level was inversely cor-
related with the total scores on the IBS Severity Scoring 
System and the Fatigue Assessment Scale.
• This study provides further evidence for the efficacy of 
FMT in treating IBS. This study suggests that intake of 
butyrate could be beneficial in the management of IBS.
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2.3  |  Superdonor
The single superdonor used in this study has been described in de-
tail previously. Briefly, he was screened according to the European 
guidelines for donors for FMT.6,7	He	was	a	healthy	36-year-old	man,	
non-smoker, not taking any medication regularly, and had a BMI of 
23.5 kg/m2. He was born via a vaginal delivery, breastfed, and had 
taken a few courses of antibiotics during his life. He exercised regu-
larly and took sport-specific dietary supplements, which made his 
diet richer than average in protein, fiber, minerals, and vitamins.4
The GA-map Dysbiosis Test® revealed that he was normobiotic, 
but his fecal bacterial profile deviated from the expected normal 
abundance in 14 of the 39 bacteria markers examined: 12 bacte-
ria in the Firmicutes phylum and 1 each in the Proteobacteria and 
Verrucomicrobia phyla.4 SCFAs were analyzed in donor's fecal sam-
ples	taken	at	0,	3,	6,	12,	and	18	months.
2.4  |  Fecal sample collection, preparation, and 
administration
Fecal	samples	were	frozen	immediately	and	kept	at	−20°C	until	they	
were delivered frozen to the laboratory, where they were kept at 
−80°C.	The	process	of	FMT	has	been	described	in	detail	previously.4 




filtered before administration. The transplant was administered to 
the distal duodenum via the working channel of a gastroscope, fol-
lowed by another 40 ml of sterile saline.
2.5  |  Symptom and quality-of-life assessments
Symptoms were assessed using the IBS-SSS and the Birmingham 
IBS Symptom (Birmingham IBS-S) questionnaires.8,9 Fatigue was 
measured using the Fatigue Assessment Scale (FAS).10 Quality of 
life was measured using the IBS Quality of Life (IBS-QoL) and Short-
Form Nepean Dyspepsia Index (SF-NDI) questionnaires.11-13 Higher 
IBS-QoL and lower SF-NDI scores indicate a better quality of life. 
Patients	who	exhibited	a	decrease	of	≥50	points	in	the	total	IBS-SSS	
score after FMT were considered responders.
2.6  |  Determination of fecal SCFA levels
The fecal samples were weighed and homogenized with a solution 
containing 3 mmol/L 2-ethylbutyric acid and 0.5 mmol/L H2SO4. 
A sample (2.5 mL) of the homogenate was vacuum-distilled, and 
the SCFA levels were determined by gas chromatography (Agilent 
7890 A; Agilent) using a capillary column (serial no. USE400345H; 
TA B L E  1   Baseline characteristics of patients
Overall Placebo 30-g FMT 60-g FMT p
Number 142 48 50 44
Age (y) 40.1 ± 13.1 41.4	±	13.6 38.9 ± 12.4 38.9 ± 13.4 .665
Sex, female/male 118/24 42/6 38/12 38/6 .248
IBS-D 52 16 20 16
IBS-C 54 21 17 16 .888
IBS-M 36 11 13 12
IBS duration (y) 15.5 ± 7.9 14.5 ± 8.0 17.2 ± 9.3 14.7 ± 5.7 .322
IBS-SSS score 311.5 ± 77.0 310.5 ± 73.8 313.3	±	76.7 310.6	±	82.4 .989
Patients with MSS 59 (41.5%) 20 (41.7%) 21 (42%) 18 (40.9%) .997
Patients with SSS 83 (58.5%) 28 (58.3%) 29 (58%) 26	(59.1%) .998
FAS score 31.5 ± 5.0 30.6	±	4.4 31.4 ± 5.3 31.4 ± 5.1 .976
Dysbiosis index 2.8 ± 1.1 2.7 ± 1.1 2.8 ± 1.0 2.9 ± 1.0 .781
Patients with dysbiosis 64% 67% 57% 67% .578
PPI medication 55 (38.7%) 19	(39.6%) 18	(36.0%) 18 (40.9%) .878
Birth control medication 84 (59.1%) 25 (52.1%) 29 (58.0%) 30	(68.2%) .286
Antimigraine medication 10 (7.0%) 3	(6.2%) 4 (8.0%) 3	(6.3%) .942
Medication against asthma/allergies 18 (12.7%) 6	(12.5%) 7 (14.0%) 5	(11.6%) .928
Medication with levothyroxine 3 (2.1%) 1 (2.1%) 0 (0%) 2 (4.5%) .311
Medication with heart/vascular drugs 6	(4.2%) 3	(6.3%) 2 (4.0%) 1 (2.3%) .635
Note: Data are mean ± SD, n, %, or n (%) values.
PPI, proton-pump inhibitor. MSS, moderate symptom severity (IBS-SSS score between 175 and 300). SSS, severe symptom severity (IBS-SSS score of 
≥300).
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F I G U R E  1   IBS-SSS scores: total (A), abdominal pain (item 1) (B), abdominal distension (item 2) (C), dissatisfaction with bowel habits (item 










0 Placebo 23.2 ± 8.1 7.3 ± 3.3 7.8 ± 4.9 7.7 ± 3.7
FMT 30 g 5.9 ± 5.7 8.3 ± 2.0 10.3 ± 4.2 7.3 ± 3.2
FMT	60	g 25.7	±	6.8 8.2 ± 2.7 9.2 ± 4.9 8.3 ± 3.2
1 month Placebo 21.3 ± 8.2 7.2 ± 3.5 6.5	±	4.9 7.5 ± 3.2
FMT 30 g 19.0 ± 8.0**** 6.0	±	3.1*** 6.9	±	4.7*** 5.7 ± 3.4*
FMT	60	g 16.4	±	8.6**** 5.1 ± 3.1**** 5.2 ± 4.0**** 6.2	±	4.9**
* p < 0.05; 
** p < 0.01; 
*** p 0.001; 
**** P < 0.0001 as compared to baseline.
TA B L E  2   The Birmingham IBS Severity 
Scoring System and its three domains in 
placebo and FMT-treated patients
F I G U R E  2   FAS scores: total (A), physical fatigue (B), and mental health (C). *p < 0.05; **p < 0.01 compared to placebo
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Agilent J&W GC columns, Agilent).14,15 Flame ionization was used 
to determine the levels of total SCFAs, acetic, propionic, isobu-
tyric, n-butyric, isovaleric, n-valeric acid, isocapronic, and n-
capronic acids, with the results expressed in units of mmol/kg wet 
weight.
2.7  |  Ethics
The study was approved by the Regional Committee for Medical 
and Health Research Ethics West, Bergen, Norway (approval no. 
2017/1197/REK vest). All subjects provided both oral and written 
consents to participate. The study was registered at www.clini caltr 
ials.gov	(NCT03822299)	and	www.crist	in.no	(ID657402).
2.8  |  Statistical analysis
The sample size required in each arm of the study was 20 patients, as 
calculated by assuming that a placebo effect was 40% and an effect 
response was 80% (α	=	0.05,	1−β = 0.80). We included 142 patients 
in order to avoid type 2 statistical errors. Differences between the 
placebo,	30,	and	60-g	FMT	groups	 in	age,	 IBS-SSS	score,	and	FAS	
score	were	analyzed	using	one-way	ANOVA	with	Tukey’s	multiple-
comparisons test as a post-test. Differences between the baseline 
and after 1 month in Birmingham IBS-S, IBS-QoL, and SF-NDI were 
analyzed using the Mann–Whitney test. Differences between the 
placebo,	30-g,	and	60-g	FMT	groups	in	sex,	overall	responses,	num-
bers of IBS subtypes included in the study, and IBS subtype medica-
tions were analyzed using the chi-squared test. The paired t test was 
used to identify differences in the SCFA levels before and 1 month 
after	FMT	in	the	placebo,	30-g,	and	60-g	groups	and	with	the	IBS	
subtypes. Control for multiple testing with the SCFA parameters was 
not done. The correlations between the changes in SCFA levels and 
the IBS-SSS and FAS scores were analyzed using the non-parametric 
Spearman test. These analyses were performed using GraphPad 
Prism (version 8). All of the authors had access to the study data and 
reviewed and approved the final version of the manuscript.
3  |  RESULTS
3.1  |  Symptom assessment
The	 response	 rates	 to	FMT	were	18.2%,	74.0%,	and	88.6%	 in	 the	
placebo,	30-g,	and	60-g	groups,	respectively.	The	response	differed	
significantly between the three groups (P < 0.0001) and between 
the	30-g	 and	60-g	FMT	groups	 (P = 0.01). The total and the sub-
items IBS-SSS scores decreased significantly after FMT (Figure 1). 
Birmingham IBS-S total score and its three domains were also signifi-
cantly reduced after FMT (Table 2). The total FAS score was also sig-
nificantly reduced after FMT. The scores for physical fatigue items 
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were not (Figure 2). The total score of IBS-QoL was significantly in-
creased, and SF-NDI total score was significantly decreased after 
FMT (Tables 3 and 4).
3.2  |  Fecal SCFA levels
The levels of total SCFAs and the individual SCFAs studied did not 
change after FMT in the placebo group (Table 5). The fecal bu-
tyric acid level increased significantly after FMT in the 30-g group 
as a whole and in the responders, but not in the non-responders 
(Table	6).	 In	the	60-g	group,	the	fecal	 levels	of	total	SCFAs,	 isobu-
tyric acid, and butyric acid were higher after FMT in the whole group 
and in the responders, but not in the non-responders. Moreover, the 
fecal levels of isovaleric and valeric acids increased in the respond-
ers after FMT (Table 7).
At the baseline, the fecal butyric acid level was significantly 
higher in IBS-D patients than in IBS-C patients and patients with 
mixed-diarrhea-and-constipation IBS (IBS-M) (Table 8). The re-
sponse to FMT did not differ significantly between the IBS subtypes 
in the placebo group regarding the levels of the total SCFAs or the 
other SCFA acids measured (Table 9). In the 30-g group, the fecal bu-
tyric acid level increased after FMT in IBS-C and IBS-M patients, but 
not in IBS-D patients. The response to FMT in terms of the changes 
in the levels of total SCFAs and other acids investigated did not differ 
between the IBS subtypes (Table 9).
In	 the	60-g	group,	 the	 response	 to	FMT	 in	 terms	of	SCFA	 lev-
els differed markedly between the IBS subtypes. The fecal butyric 
acid level increased for all of the IBS subtypes. The total fecal SCFA 
level increased in both IBS-D and IBS-C patients, but not in IBS-M 
patients. The fecal levels of isovaleric and valeric acids increased in 
IBS-D patients, but not in IBS-C or IBS-M patients (Table 9).
The butyric acid level was inversely correlated with the IBS-SSS 
and FAS scores (p = 0.005, r	=	−0.3,	in	both;	Figure	3),	while	the	SCFA	
level was inversely correlated with the IBS-SSS score (p = 0.005, 
r	=	−0.4).	Isobutyric	acid,	isovaleric	acid,	and	valeric	acids	did	not	cor-
relate with the IBS-SSS total score (p = 0.2; r	=	−0.2,	p = 0.2; r = 0.2, 
and p = 0.2; r	=	−	0.1,	respectively).	They	did	not	correlate	either	with	
FAS total score (p	=	0.6;	r = 0.7, p = 0.5; r = 0.1, and p = 0.9; r	=	−0.2,	
respectively).
TA B L E  4   SF-NDI total score and scores on the five subscales of this scale in placebo and FMT-treated patients
Time Group Total score 1 2 3 4 5
0 Placebo 30.0	±	7.6 6.4	±	1.8 5.7 ± 1.9 6.8	±	1.8 5.4 ± 2.1 5.4 ± 1.8
30-g FMT 30.3 ± 7.5 6.2	±	1.6 5.8 ± 2.1 7.2 ± 2.1 5.4 ± 1.7 5.6	±	2.3
60-g	FMT 31.1 ± 8.2 6.6	±	1.9 5.9 ± 2.3 7.1 ± 1.8 5.8 ± 1.9 5.7 ± 2.1
1 month Placebo 28.5 ± 8.7 6.0	±	2.1 5.4 ± 2.2 6.7	±	2.2 4.9 ± 2.1 5.3 ± 2.2
30-g FMT 28.1.6	±	8.1* 5.2 ± 1.9** 5.1 ± 2.1 6.5	±	2.2 4.6	±	1.7* 5.1 ± 2.2
60-g	FMT 25.2 ± 9.9** 5.2 ± 2.1*** 4.9 ± 2.4* 5.7 ± 2.3** 4.6	±	2.0** 5.0 ± 2.7
Note: Data are mean ± SD values. SF-NDI subscales: 1, tension; 2, interference with daily activities; 3, disruption to eating/drinking; 4, knowledge 
about/control over disease symptoms; and 5, interference with work/study.
*p < 0.05; 
**p < 0.01; 
***Compared to baseline. 
TA B L E  5   SCFA levels in the feces of the placebo group before and after FMT
Acid
Total group Responders Non-responders
Before 
FMT After FMT p Before FMT After FMT p Before FMT After FMT p
Total SCFAs 72.7	±	36.7 68.2	±	23.0 0.507 86.6	±	36.0 83.6	±	25.6 >0.999 72.7	±	36.7 69.0	±	23.2 0.914
Acetic acid 41.6	±	17.5 40.4 ± 14.5 0.634 48.3 ± 19.4 47.7 ± 15.9 0.886 41.0 ± 17.4 39.7 ± 14.4 0.828
Propionic acid 12.1	±	7.6 11.4 ± 5,0 0.515 15.6	±	8.4 13.6	±	5.4 >0.999 11.8	±	7.6 11.2 ± 5.0 0.945
Isobutyric acid 1.5 ± 1.5 1.3 ± 0.8 0.466 1.8 ± 0.4 1.5 ± 1.0 0.800 1,4 ± 1.5 1.3 ± 0.8 0.485
Butyric acid 13.7 ± 8.8 12.2	±	6.3 0.193 18.2 ± 13.9 16.6	±	8.5 0.886 13.3 ± 8.3 11.8	±	6.0 0.701
Isovaleric acid 2.2 ± 2.3 1.9 ± 1.3 0.372 2.6	±	0.9 2.2 ± 1.7 0.914 2.2 ± 2.4 1.9 ± 1.3 0.738
Valeric acid 1.7 ± 1.5 1.4 ± 0.7 0.340 2.0 ± 0.7 1.8 ± 0.8 0.629 1.7 ± 1.5 1.4 ± 0.7 0.825
Isocapronic acid 0.10 ± 0.04 0.01 ± 0.07 0.860 0.40 ± 0.3 0.60	±	0.9 0.771 0.50 ± 0.7 0.40 ± 0.7 0.768
Capronic acid 0.5 ± 0.7 0.5 ± 0.7 0.891 0.03 ± 0.05 0.0 ± 0.0 >0.999 0.01 ± 0.04 0.1 ± 0.08 0.936
Note: Data are mean ± SD values expressed in units of mmol/kg wet weight.
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3.3  |  Adverse events
The adverse events were presented in detail previously, shortly 
about 20% of the patients treated with FMT experienced abdomi-
nal pain, cramping, tenderness, diarrhea, or constipation, compared 
with 2% of those in the placebo group. These adverse events were 
mild, self-limiting, and occurred during the first 2 days after FMT.4
4  |  DISCUSSION
The present study showed that FMT-induced marked changes in the 
fecal SCFAs levels in patients with IBS. These changes varied with 
the transplant dose, while the alterations in the SCFAs levels in re-
sponse to FMT differed with the IBS subtype. In both the 30-g and 
60-g	groups,	the	fecal	butyric	acid	level	increased	significantly	in	the	
responders	after	FMT.	However,	in	the	60-g	group,	the	fecal	levels	
of total SCFAs, isobutyric, isovaleric, and valeric acids increased in 
the responders following FMT.
At the baseline, the fecal butyric acid level was lower in IBS-C 
and IBS-M patients than in IBS-D patients. This finding agrees with 
a previous report of the butyric acid level being lower in IBS-C pa-
tients than in healthy subjects.16 The propionic acid level did not 
differ significantly between the IBS subtypes in the present study, 
which disagrees with the previous report of the propionic acid level 
being lower in IBS-C patients than in healthy subjects.16 While the 
fecal butyric acid level increased in IBS-C and IBS-M patients after 
30-g FMT, that in IBS-D patients did not change. The fecal butyric 
acid	 levels	 increased	 in	 all	 IBS	 subtypes	 following	 60-g	 FMT.	 The	
total fecal SCFA and isobutyric acid levels increased in both IBS-D 
and IBS-C patients, but not in IBS-M patients. The fecal levels of 
isovaleric and valeric acids increased only in IBS-D patients. The fer-
mentation and production of SCFAs occur in the proximal colon and 
most of the SCFAs are absorbed rapidly by the colon epithelial cells, 
which means that the intestinal transit time affects the fecal SCFA 
levels.17 The differences in the fecal levels of different SCFAs be-
tween the IBS subtypes may therefore be caused by differences in 
the intestinal transit time between these subtypes. SCFAs regulate 
the secretion and absorption of water and electrolytes and intestinal 
motility.18,19 SCFAs increase also the secretion and upregulate the 
gene expression of peptide YY,20,21 which is a mediator of the ileal 
brake and stimulates the absorption of water and electrolytes in the 
large intestine.18,22,23 It is also possible that the differences in the 
SCFA levels between the IBS subtypes were due to differences in 
intestinal secretion, absorption, and motility.
In our previous study involving the same cohort of patients, the 
fecal levels of Eubacterium and Lactobacillus spp. were significantly 
increased after FMT.4 Eubacterium spp. are among the bacteria that 
produce butyrate upon carbohydrate fermentation, and treatment 
with Lactobacillus spp. can reportedly increase the fecal butyrate 
level.24,25 These previously reported changes in the intestinal bac-
terial profile can explain the increase in the fecal butyric acid level 
Acid IBS-D IBS-C IBS-M p
Total SCFAs 72.8	±	26.9 66.4	±	26.4 86.3	±	61.1 .412
Acetic acid 45.0	±	16.7 38.5 ± 15.9 49.0 ± 27.8 238
Propionic acid 13.4 ± 7.7 11.6	±	5.8 13.9 ± 13.3 .305
Isobutyric acid 1.3 ± 0.8 1.4 ± 0.8 1.8 ± 2.1 .676
Butyric acid 16.3	±	9.9 10.7 ± 7.1* 10.0 ± 7.1* .009
Isovaleric acid 1.9 ± 1.3 2.0 ± 1.2 3.0 ± 3.8 .725
Valeric acid 1.6	±	0.8 1.8 ± 2.0 2.0 ± 2.2 .851
Isocapronic acid 0.017 ± 0.048 0.0 ± 0.0 0.04 ± 0.021 .155
Capronic acid 0.228 ± 0 0.400 ± 0.723 0.200 ± 0.520 .523
Note: Data are mean ± SD values expressed in units of mmol/kg wet weight.
* Statistically significant compared to IBS-D. 
TA B L E  8   Differences between the IBS 
subgroups at the baseline
F I G U R E  3   Correlation between butyric acid levels and IBS-SSS total scores (A) and FAS total score (B)
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in	both	the	30-g	and	60-g	groups	after	FMT	observed	in	this	study.	
Butyrate is an important source of energy for colonic epithelial 
cells, and its lack can cause mucosal atrophy.19 Butyrate also affects 
the immune response, modulates the oxidative stress of the host, 
and decreases intestinal cell permeability and intestinal motility.22 
Furthermore, butyrate appears to modulate colonic hypersensitiv-
ity, and treatment with butyrate reduces the abdominal pain in pa-
tients with IBS.26-28 In the present study, the butyric acid level was 
inversely correlated with abdominal symptoms and fatigue, suggest-
ing its role in the pathophysiology of IBS. The role of the increased 
levels	of	 isobutyric,	 isovaleric,	 and	valeric	 acids	 in	 the	60-g	group	
after FMT is not clear. Further studies using animal models may shed 
light on the pathophysiology of SCFAs in IBS.29
One of the main strengths of this study is that it investigated 
a relatively large cohort of patients with IBS, included three of the 
four IBS subtypes, and used a single superdonor. However, the study 
also had limitations: It did not include the unclassified IBS subtype 
(IBS-U), it did not investigate the long-term effects of FMT on fecal 
SCFA levels, and the cohort of included patients were those who did 
respond to the modified NICE diet; this means that the outcomes 
cannot be applied to the whole IBS population. Moreover, it is a 
single-center study whose main findings are yet to be replicated in 
larger multicenter studies.
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